/

Empresas

Zu

No verificado

Zura Bio Limited

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud

33 Comunicados de prensa

Ver todos los comunicados de prensa

29/06/2026

Salud

Higiene alimentaria

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Industria

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

Fuente

Zura Bio Limited

Editor

1.00

0

14/05/2026

Mercado de valores

Finanzas

Ciencia

Biotecnología

Farmacéutica

Sanidad

Salud

Medicina - Varios

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fuente

Zura Bio Limited

Editor

1.00

0

13/05/2026

Mercado laboral

Ciencia

Biotecnología

Farmacéutica

Sanidad

Salud

Medicina - Varios

Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer

Fuente

Zura Bio Limited

Editor

1.00

0

07/05/2026

Mercado de valores

Ciencia

Biotecnología

Farmacéutica

Sanidad

Salud

Medicina - Varios

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

Fuente

Zura Bio Limited

Editor

1.00

0

04/05/2026

Finanzas

Biotecnología

Farmacéutica

Salud

Medicina - Varios

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fuente

Zura Bio Limited

Editor

1.00

0

19/03/2026

Mercado de valores

Ciencia

Biotecnología

Farmacéutica

Sanidad

Salud

Medicina - Varios

Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates

Fuente

Zura Bio Limited

Editor

1.00

0

05/03/2026

Eventos

Industria

Biotecnología

Farmacéutica

Salud

Medicina - Varios

Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress

Fuente

Zura Bio Limited

Editor

1.00

0

02/03/2026

Eventos

Web y redes sociales

Ciencia

Biotecnología

Farmacéutica

Salud

Higiene alimentaria

Medicina - Varios

Zura Bio to Participate in Upcoming Investor Conferences

Fuente

Zura Bio Limited

Editor

1.00

0

27/02/2026

Finanzas

Biotecnología

Farmacéutica

Salud

Medicina - Varios

Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Fuente

Zura Bio Limited

Editor

1.00

0

25/02/2026

Finanzas

Salud

Sanidad

Medicina - Varios

Farmacéutica

Biotecnología

Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants

Fuente

Zura Bio Limited

Editor

1.00

0

Seguidores

0

Compatibilidad

0